Cell-based products dominate advanced therapy pipeline in EU
This article was originally published in Scrip
Executive Summary
The approval rate for advanced therapy medicinal products (ATMPs) may be slow, but there are many more drugs coming through the R&D pipeline, as evidenced by the level of scientific advice being given by the European Medicines Agency's Committee on Advanced Therapies (CAT), according to Paula Salmikangas, the Finnish researcher who has just been promoted from vice-chair of the committee to chair for a three-year period.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.